SG11202105697SA - Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one - Google Patents
Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-oneInfo
- Publication number
- SG11202105697SA SG11202105697SA SG11202105697SA SG11202105697SA SG11202105697SA SG 11202105697S A SG11202105697S A SG 11202105697SA SG 11202105697S A SG11202105697S A SG 11202105697SA SG 11202105697S A SG11202105697S A SG 11202105697SA SG 11202105697S A SG11202105697S A SG 11202105697SA
- Authority
- SG
- Singapore
- Prior art keywords
- dihydroindolizine
- fluoropyridine
- tetrazole
- imidazole
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018224434 | 2018-11-30 | ||
| PCT/JP2019/046893 WO2020111268A1 (en) | 2018-11-30 | 2019-11-29 | Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105697SA true SG11202105697SA (en) | 2021-06-29 |
Family
ID=70853323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105697SA SG11202105697SA (en) | 2018-11-30 | 2019-11-29 | Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210395250A1 (en) |
| EP (1) | EP3888653A4 (en) |
| JP (1) | JP7196931B2 (en) |
| KR (1) | KR20210097119A (en) |
| CN (1) | CN113226312A (en) |
| AU (1) | AU2019390094A1 (en) |
| BR (1) | BR112021010476A2 (en) |
| CA (1) | CA3121447A1 (en) |
| IL (1) | IL283481A (en) |
| MX (1) | MX2021006147A (en) |
| PH (1) | PH12021551219A1 (en) |
| SG (1) | SG11202105697SA (en) |
| TW (1) | TWI826599B (en) |
| WO (1) | WO2020111268A1 (en) |
| ZA (1) | ZA202103692B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240108639A1 (en) * | 2020-12-11 | 2024-04-04 | Board Of Regents, The University Of Texas System | Compositions and methods of making cocrystals using dielectric heating with dispersive and distributive mixing |
| JP2024125436A (en) * | 2021-07-20 | 2024-09-19 | 小野薬品工業株式会社 | Method for producing imidazole compounds |
| TWI833610B (en) * | 2022-03-21 | 2024-02-21 | 大陸商上海濟煜醫藥科技有限公司 | Method and intermediates for preparing tricyclic compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201403402VA (en) | 2011-12-21 | 2015-01-29 | Ono Pharmaceutical Co | Compounds |
| JP2016093285A (en) | 2014-11-13 | 2016-05-26 | 株式会社ユニバーサルエンターテインメント | Game machine |
| US10065955B2 (en) * | 2014-12-10 | 2018-09-04 | Ono Pharmaceutical Co., Ltd. | Dihydroindolizinone derivative |
| JP6992284B2 (en) * | 2016-06-06 | 2022-01-13 | 小野薬品工業株式会社 | Pharmaceutical composition containing dihydroindridinone derivative |
-
2019
- 2019-11-29 AU AU2019390094A patent/AU2019390094A1/en active Pending
- 2019-11-29 TW TW108143720A patent/TWI826599B/en active
- 2019-11-29 JP JP2020557880A patent/JP7196931B2/en active Active
- 2019-11-29 EP EP19888537.8A patent/EP3888653A4/en not_active Withdrawn
- 2019-11-29 BR BR112021010476-3A patent/BR112021010476A2/en unknown
- 2019-11-29 WO PCT/JP2019/046893 patent/WO2020111268A1/en active Application Filing
- 2019-11-29 MX MX2021006147A patent/MX2021006147A/en unknown
- 2019-11-29 SG SG11202105697SA patent/SG11202105697SA/en unknown
- 2019-11-29 CA CA3121447A patent/CA3121447A1/en active Pending
- 2019-11-29 US US17/297,649 patent/US20210395250A1/en not_active Abandoned
- 2019-11-29 CN CN201980079268.XA patent/CN113226312A/en active Pending
- 2019-11-29 KR KR1020217016005A patent/KR20210097119A/en active Search and Examination
-
2021
- 2021-05-26 IL IL283481A patent/IL283481A/en unknown
- 2021-05-27 PH PH12021551219A patent/PH12021551219A1/en unknown
- 2021-05-28 ZA ZA2021/03692A patent/ZA202103692B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210395250A1 (en) | 2021-12-23 |
| CN113226312A (en) | 2021-08-06 |
| WO2020111268A1 (en) | 2020-06-04 |
| JPWO2020111268A1 (en) | 2021-10-14 |
| BR112021010476A2 (en) | 2021-08-24 |
| EP3888653A4 (en) | 2022-08-24 |
| MX2021006147A (en) | 2021-06-23 |
| IL283481A (en) | 2021-07-29 |
| EP3888653A1 (en) | 2021-10-06 |
| AU2019390094A1 (en) | 2021-06-17 |
| JP7196931B2 (en) | 2022-12-27 |
| TW202039485A (en) | 2020-11-01 |
| KR20210097119A (en) | 2021-08-06 |
| TWI826599B (en) | 2023-12-21 |
| ZA202103692B (en) | 2023-03-29 |
| CA3121447A1 (en) | 2020-06-04 |
| PH12021551219A1 (en) | 2021-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202103692B (en) | Novel crystal of (3s)-3-[2-(6-amino-2-fluoropyridine-3-yl)-4-fluoro-1h-imidazole-5-yl]-7-[5-chloro-2-(1h-tetrazole-1-yl)phenyl]-2,3-dihydroindolizine-5(1h)-one | |
| EP3746436A4 (en) | Fused ring compounds | |
| IL282916A (en) | Fused ring compounds | |
| EP3877779A4 (en) | Integrated cooling solution for spinning sensors | |
| EP3738347A4 (en) | Conditional handover procedures | |
| IL279173A (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL280762A (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL283333A (en) | New heterocyclic compounds | |
| SI3448848T1 (en) | Polymorphic form of n-(6-(2-hydroxypropan-2-yl)-2-(2-(methylsulphonyl)ethyl)-2h-indazol-5-yl)-6-(trifluoromethyl)pyridine-2-carboxamide | |
| EP3919055A4 (en) | Heterocyclic compound | |
| EP4029479A4 (en) | Cage holder of spinal fusion cage | |
| EP3263553A4 (en) | Crystalline modification of n-(2-(3-phenylureido)phenyl)benzenesulfonamide and recording material using same | |
| IL289595A (en) | Heterocyclic compounds | |
| EP4066893A4 (en) | Heterocyclic compound | |
| IL288987A (en) | New heterocyclic compounds | |
| IL290367A (en) | Fused ring heteroaryl compounds as ripk1 inhibitors | |
| KR102268335B9 (en) | Colposcopy | |
| GB201915191D0 (en) | Novel heterocyclic compounds | |
| EP4081509A4 (en) | Novel compounds suitable for the treatment of dyslipidemia | |
| PL4010124T4 (en) | Centrifuge | |
| EP4005637A4 (en) | Heterocyclic compound | |
| GB201913321D0 (en) | Disposable centrifuge pot | |
| EP3980406A4 (en) | Heterocyclic compounds | |
| IL266615A (en) | Glasses of controlled | |
| EP4046688A4 (en) | Heterocyclic compound |